- Home
- AGEN vs AKA Comparison
AGEN vs AKA Comparison
Compare AGEN & AKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | AKA |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 121.7M |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AGEN | AKA |
|---|---|---|
| Price | $3.38 | $9.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $14.50 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 486.5K | 3.2K |
| Earning Date | 03-16-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $42,877,086.00 | ★ $600,208,000.00 |
| Revenue This Year | $61.42 | $5.94 |
| Revenue Next Year | N/A | $4.96 |
| P/E Ratio | $8.89 | ★ N/A |
| Revenue Growth | ★ 89.95 | 4.44 |
| 52 Week Low | $1.38 | $7.00 |
| 52 Week High | $7.34 | $16.38 |
Technical Indicators
Market Signals| Indicator | AGEN | AKA |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 48.93 |
| Support Level | $2.91 | $9.31 |
| Resistance Level | $4.72 | $11.71 |
| Average True Range (ATR) | 0.27 | 0.48 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 38.97 | 64.71 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.